Eli Lilly and Company (LLY) Earnings Call Transcripts
Eli Lilly and Company's Latest Earnings Call - Q3 FY2026
In Q3 2026, Eli Lilly reported robust financial results with revenue reaching nearly $7 billion, a 39% increase compared to Q3 2025. The company raised its full-year revenue guidance to between $91 billion and $92 billion, reflecting strong performance in its incretin portfolio, particularly Mounjaro and Zepbound. Non-GAAP earnings per share increased to $7.48, up from $7.02 in the prior year, indicating solid operational efficiency and growth across therapeutic areas.
Reported metrics
| Metric | Value |
|---|---|
| Full Year Revenue Guidance | $91B - $92B (positive) |
| Gross Margin | 84.4% (positive) |
| U.S. Revenue Growth | 34% (positive) |
| International Revenue Growth (China) | 62% (positive) |
| Total Prescriptions for Obesity | 82% (positive) |
| Mounjaro Revenue | $16B (positive) |
Guidance from management
Management raised its full-year revenue guidance to between $91 billion and $92 billion, reflecting strong performance and confidence in future growth. Non-GAAP earnings per share guidance was also increased to $35 to $36.
What management said
Great. Thank you, Dave. We'd like to take questions from as many callers as possible. So to that end, consistent with prior quarters, please limit yourself to one question. Operator, please provide the instructions for how to join the queue and then we're ready for the first caller.
Great. Thanks, Asad. I think we'll start maybe with international and go to Patrick to talk a bit about some of the U.S. launches and then Ilya maybe a couple of nuggets on the U.S. as well.
What analysts pressed on
Analysts expressed concerns regarding the sustainability of revenue growth amid pricing pressures and the potential for increased competition in the incretin market. There were questions about the long-term impact of the Medicare Bridge program and its ability to maintain momentum.
Main topics on the call
- Revenue Growth Acceleration — Eli Lilly's revenue grew 39% year-over-year, driven by strong sales in its oncology, immunology, and neuroscience portfolios. Management noted, "Revenue grew nearly $7 billion compared to Q3 2025, and our key product rev...
- Guidance Increase — The company raised its full-year revenue guidance by approximately $10 billion, now expecting revenue between $91 billion and $92 billion. Lucas Montarce stated, "We now expect full year revenue to be between $91 billion...
- Pipeline Advancements — Lilly advanced its pipeline with several key regulatory approvals and ongoing clinical trials. Notably, retatrutide demonstrated superior weight loss compared to semaglutide, with management asserting, "Retatrutide deliv...
- Medicare GLP-1 Bridge Program Success — The Medicare GLP-1 Bridge program has seen strong uptake, with 75% of participants opting for injectable therapies. Management highlighted, "7 out of 10 in total choosing Lilly medicine," showcasing the program's effecti...
Read the full Eli Lilly and Company transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 110 calls on record spanning January 14, 2020 to October 29, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 110 Eli Lilly and Company earnings call transcripts on record, spanning January 14, 2020 to October 29, 2026. Based on this history, Eli Lilly and Company reports quarterly. The most recent call on file is dated October 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- LLY
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 110
- First call
- January 14, 2020
- Most recent
- October 29, 2026
- Reporting cadence
- quarterly